ArticleInternational journal of clinical and experimental pathology2018
miRNA-627 inhibits cell proliferation and cell migration, promotes cell apoptosis in prostate cancer cells through upregulating MAP3K1, PTPRK and SRA1.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- MAP3K1: A Multifunctional Kinase at the Crossroads of Cancer Progression and Tumor Suppression.Cells · 2026Review
- Exosomal miR-223-3p from mesenchymal stem cells targets FBXW7 to inhibit intervertebral disc degeneration: mechanism insights.Journal of orthopaedic surgery and research · 2025Article
- Role and mechanistic study of long non-coding RNA maternally expressed gene 3 in gastric cancer (Review).Oncology letters · 2025Review
- PTPRK promotes resiniferatoxin-induced postherpetic neuralgia via activating DUSP1/p38 MAPK signaling pathway in dorsal root ganglia.Scientific reports · 2025Article
- Long noncoding RNA steroid receptor RNA activator 1 inhibits proliferation and glycolysis of esophageal squamous cell carcinoma.World journal of gastrointestinal oncology · 2024Article
- miR-6884-5p inhibits proliferation and epithelial-mesenchymal transition in non-small cell lung cancer cells.Heliyon · 2024Article
- Mitogen-activated protein kinase kinase kinase 1 facilitates the temozolomide resistance and migration of GBM via the MEK/ERK signalling.Journal of cellular and molecular medicine · 2024Article
- miR-328-5p Induces Human Intervertebral Disc Degeneration by Targeting WWP2.Oxidative medicine and cellular longevity · 2022Article
- miR-148a, miR-152 and miR-200b promote prostate cancer metastasis by targeting DNMT1 and PTEN expression.Oncology letters · 2021Article
- Oral Epithelial Cells Distinguish betweenmSystems · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivemiRNAs, altered expression manner in prostate cancer, have involved in cancer development by regulating proliferation, differentiation, invasion, metabolism and apoptosis. Recently, it has been found that miRNA-627 might mediate colorectal cancer cells as a tumor-suppressor. However, its role on prostate cancer cells remains unknown.
methodsFollowing transfection with miRNA-627, miRNA-627 expression, cell proliferation, cell cycle, cell apoptosis, migration assay, and real-time PCR analysis were performed in prostate cancer cells.
resultsIt was found that miRNA-627 inhibited cell proliferation, retarded cell cycle and cell migration in prostate cancer cells. Additionally, miRNA-627 promoted cell apoptosis and upregulated the mRNA levels of MAP3K1, PTPRK and SRA1.
conclusionCollectively, miRNA-627 interrupts prostate cancer development as suppressing cell proliferation, migration and promoting cell apoptosis and tumor suppressor genes expression, which might provide promising therapeutic effect in the treatment of prostate cancer.
Indexed as
Identifiers
31938108PMC6957944What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.